RxDoctor Payments Data

Mary Linville

Family · Lafayette, TNNPI 1497788350

Payments from drug & device makers

$1,077in general payments, 2019–2025

Across 49 payments — averaging $21.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$307
  • Otsuka America Pharmaceutical, Inc.$202
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$168
  • Teva Pharmaceuticals USA, Inc.$114
  • Johnson & Johnson$94
  • Sunovion Pharmaceuticals Inc.$67
  • plus $126 from 5 others

What the payments were for

  • Food & beverage$98792%
  • Education$908%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,077 in reported general payments places this provider in the 65th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$6,869
Medicare patients
55
Services billed
121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate35$300,626
VraylarCariprazine Hcl82$137,084
Abilify MaintenaAripiprazole13$37,805
RexultiBrexpiprazole22$29,562
TrintellixVortioxetine Hydrobromide27$15,670
Aripiprazole90$3,587
Ziprasidone Hcl34$2,796
Buspirone Hcl165$2,615
Quetiapine Fumarate121$1,968
Olanzapine55$1,738
Hydroxyzine Hcl73$1,737
Mirtazapine123$1,736
Trazodone Hcl219$1,638
Atomoxetine Hcl17$1,625
Oxcarbazepine37$1,528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$35$300,62635 claims
AbbVieVraylar$44$137,08482 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$202$67,36735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,706 family providers in Tennessee.

Other family in Lafayette

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →